Vasoactive peptides and the pathogenesis of pulmonary hypertension: Role and potential therapeutic application

Handbook of Experimental Pharmacology

Volumn 218, Issue , 2013, Pages 477-511

  Baliga, Reshma S ^a   MacAllister, Raymond J ^b   Hobbs, Adrian J ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Adrenomedullin; Angiotensin II; Calcitonin gene related peptide; cAMP; cGMP; Endothelin 1; Natriuretic peptides; Neutral endopeptidase; Phosphodiesterase; Pulmonary hypertension; Somatostatin; Vasoactive intestinal peptide; Vasoconstriction; Vasodilatation

Indexed keywords

ADENYLATE CYCLASE; ADRENOMEDULLIN; ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CALCITONIN GENE RELATED PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIN 1; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; MEMBRANE METALLOENDOPEPTIDASE; NATRIURETIC FACTOR; REACTIVE OXYGEN METABOLITE; SOMATOSTATIN 14; SOMATOSTATIN 28; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; BIOLOGICAL ACTIVITY; BLOOD VESSEL PERMEABILITY; CELL PROLIFERATION; DISEASE SEVERITY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; LUNG ARTERY PRESSURE; LUNG CIRCULATION; LUNG FIBROSIS; LUNG VASCULAR RESISTANCE; LUNG VASOCONSTRICTION; NONHUMAN; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SECRETION; PULMONARY HYPERTENSION; SMOOTH MUSCLE FIBER; VASODILATATION;

ADRENOMEDULLIN; ANIMALS; CALCITONIN GENE-RELATED PEPTIDE; ENDOTHELIN-1; HUMANS; HYPERTENSION, PULMONARY; NATRIURETIC PEPTIDES; PEPTIDES; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84893043510     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-38664-0-19     Document Type: Article

References (293)

1. Abassi ZA, Kotob S, Golomb E, Pieruzzi F, Keiser HR (1995) Pulmonary and renal neutral endopeptidase EC 3.4.24.11 in rats with experimental heart failure. Hypertension 25:1178-1184
2. Ahluwalia A, Hobbs AJ (2005) Endothelium-derived C-type natriuretic peptide: More than just a hyperpolarizing factor. Trends Pharmacol Sci 26:162-167
3. Ahluwalia A, MacAllister RJ, Hobbs AJ (2004) Vascular actions of natriuretic peptides. Cyclic GMP-dependent and-independent mechanisms. Basic Res Cardiol 99:83-89
4. Aiyar N, Rand K, Elshourbagy NA, Zeng Z, Adamou JE, Bergsma DJ, Li Y (1996) A cDNA encoding the calcitonin gene-related peptide type 1 receptor. J Biol Chem 271:11325-11329
5. Aiyar N, Disa J, Siemens IR, Nambi P (1997) Differential effects of guanine nucleotides on [125I]-hCGRP(8-37) binding to porcine lung and human neuroblastoma cell membranes. Neuropeptides 31:99-103
6. Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM (1982) Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 298:240-244
7. Anand-Srivastava MB, Sehl PD, Lowe DG (1996) Cytoplasmic domain of natriuretic peptide receptor-C inhibits adenylyl cyclase. Involvement of a pertussis toxin-sensitive G protein. J Biol Chem 271:19324-19329
8. Ando K, Fujita T (2003) Lessons from the adrenomedullin knockout mouse. Regul Pept 112: 185-188
9. Ando S, Rahman MA, Butler GC, Senn BL, Floras JS (1995) Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension 26:1160-;1166
10. Angus RM, McCallum MJ, Hulks G, Thomson NC (1993) Bronchodilator, cardiovascular, and cyclic guanylyl monophosphate response to high-dose infused atrial natriuretic peptide in asthma. Am Rev Respir Dis 147:1122-1125
11. Asnicar MA, Koster A, Heiman ML, Tinsley F, Smith DP, Galbreath E, Fox N, Ma YL, Blum WF, Hsiung HM (2002) Vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating peptide receptor 2 deficiency in mice results in growth retardation and increased basal metabolic rate. Endocrinology 143:3994-4006
12. Backlund T, Palojoki E, Saraste A, Gronholm T, Eriksson A, Lakkisto P, Vuolteenaho O, Nieminen MS, Voipio-Pulkki LM, Laine M, Tikkanen I (2003) Effect of vasopeptidase inhibitor omapatrilat on cardiomyocyte apoptosis and ventricular remodeling in rat myocardial infarction. Cardiovasc Res 57:727-737
13. Baliga RS, Zhao L, Madhani M, Lopez-Torondel B, Visintin C, Selwood D, Wilkins MR, MacAllister RJ, Hobbs AJ (2008) Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension. Am J Respir Crit Care Med 178:861-869
14. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334:296-302
15. Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, McLaughlin V, Hill N, Tapson VF, Robbins IM, Zwicke D, Duncan B, Dixon RA, Frumkin LR (2004) Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169:441-447
16. Belvisi MG, Miura M, Stretton D, Barnes PJ (1993) Endogenous vasoactive intestinal peptide and nitric oxide modulate cholinergic neurotransmission in guinea-pig trachea. Eur J Pharmacol 231:97-102
17. Bennett BD, Bennett GL, Vitangcol RV, Jewett JR, Burnier J, Henzel W, Lowe DG (1991) Extracellular domain-IgG fusion proteins for three human natriuretic peptide receptors. Hormone pharmacology and application to solid phase screening of synthetic peptide antisera. J Biol Chem 266:23060-23067
18. Bevan EG, Connell JM, Doyle J, Carmichael HA, Davies DL, Lorimer AR, McInnes GT (1992) Candoxatril, a neutral endopeptidase inhibitor: Efficacy and tolerability in essential hypertension. J Hypertens 10:607-613
19. Bianchi C, Gutkowska J, Thibault G, Garcia R, Genest J, Cantin M (1985) Radioautographic localization of 125I-atrial natriuretic factor (ANF) in rat tissues. Histochemistry 82:441-452
20. Bivalacqua TJ, Hyman AL, Kadowitz PJ, Paolocci N, Kass DA, Champion HC (2002) Role of calcitonin gene-related peptide (CGRP) in chronic hypoxia-induced pulmonary hypertension in the mouse. Influence of gene transfer in vivo. Regul Pept 108:129-133
21. Blais C Jr, Fortin D, Rouleau JL, Molinaro G, Adam A (2000) Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts. J Pharmacol Exp Ther 295:621-626
22. Borson DB (1991) Roles of neutral endopeptidase in airways. Am J Physiol 260:L212-L225
23. Brain SD, Williams TJ, Tippins JR, Morris HR, MacIntyre I (1985) Calcitonin gene-related peptide is a potent vasodilator. Nature 313:54-56
24. Brum JM, Bove AA, Sufan Q, Reilly W, Go VL (1986) Action and localization of vasoactive intestinal peptide in the coronary circulation: Evidence for nonadrenergic, noncholinergic coronary regulation. J Am Coll Cardiol 7:406-413
25. Burrell LM, Droogh J, Mani V, Rockell MD, Farina NK, Johnston CI (2000) Antihypertensive and antihypertrophic effects of omapatrilat in SHR. Am J Hypertens 13:1110-1116
26. Cargill RI, Lipworth BJ (1995a) Pulmonary vasorelaxant activity of atrial natriuretic peptide and brain natriuretic peptide in humans. Thorax 50:183-185
27. Cargill RI, Lipworth BJ (1995b) The role of the renin-angiotensin and natriuretic peptide systems in the pulmonary vasculature. Br J Clin Pharmacol 40:11-18
28. Cargill RI, Lipworth BJ (1996) Atrial natriuretic peptide and brain natriuretic peptide in cor pulmonale. Hemodynamic and endocrine effects. Chest 110:1220-1225
29. Carstairs JR, Barnes PJ (1986) Visualization of vasoactive intestinal peptide receptors in human and guinea pig lung. J Pharmacol Exp Ther 239:249-255
30. Champion HC, Bivalacqua TJ, Toyoda K, Heistad DD, Hyman AL, Kadowitz PJ (2000) In vivo gene transfer of prepro-calcitonin gene-related peptide to the lung attenuates chronic hypoxiainduced pulmonary hypertension in the mouse. Circulation 101:923-930
31. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, Rubin LJ (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study. Lancet 358:1119-1123
32. Chattergoon NN, D'Souza FM, Deng W, Chen H, Hyman AL, Kadowitz PJ, Jeter JR Jr (2005) Antiproliferative effects of calcitonin gene-related peptide in aortic and pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 288:L202-L211
33. Chauhan SD, Nilsson H, Ahluwalia A, Hobbs AJ (2003) Release of C-type natriuretic peptide accounts for the biological activity of endothelium-derived hyperpolarizing factor. Proc Natl Acad Sci USA 100:1426-1431
34. Chen YF (2005) Atrial natriuretic peptide in hypoxia. Peptides 26:1068-1077
35. Chen RY, Guth PH (1995) Interaction of endogenous nitric oxide and CGRP in sensory neuroninduced gastric vasodilation. Am J Physiol 268:G791-G796
36. Chen SJ, Chen YF, Meng QC, Durand J, Dicarlo VS, Oparil S (1995) Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 79:2122-2131
37. Chen YF, Feng JA, Li P, Xing D, Ambalavanan N, Oparil S (2006) Atrial natriuretic peptidedependent modulation of hypoxia-induced pulmonary vascular remodeling. Life Sci 79: 1357-1365
38. Christophe J, Waelbroeck M, Chatelain P, Robberecht P (1984) Heart receptors for VIP, PHI and secretin are able to activate adenylate cyclase and to mediate inotropic and chronotropic effects. Species variations and physiopathology. Peptides 5:341-353
39. Chrysant SG, Chrysant GS (2012) Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors. Am J Cardiol 109:1681-1685
40. Chusho H, Tamura N, Ogawa Y, Yasoda A, Suda M, Miyazawa T, Nakamura K, Nakao K, Kurihara T, Komatsu Y, Itoh H, Tanaka K, Saito Y, Katsuki M, Nakao K (2001) Dwarfism and early death in mice lacking C-type natriuretic peptide. Proc Natl Acad Sci USA 98:4016-4021
41. Cohen AJ, King TE Jr, Gilman LB, Magill-Solc C, Miller YE (1998) High expression of neutral endopeptidase in idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells. Am J Respir Crit Care Med 158:1593-1599
42. Colwell CS, Michel S, Itri J, Rodriguez W, Tam J, Lelievre V, Hu Z, Liu X, Waschek JA (2003) Disrupted circadian rhythms in VIP-and PHI-deficient mice. Am J Physiol Regul Integr Comp Physiol 285:R939-R949
43. Dani C, Pavoni V, Corsini I, Longini M, Gori G, Giannesello L, Perna A, Gritti G, Paternostro F, Forestieri A, Buonocore G, Rubaltelli FF (2007) Inhaled nitric oxide combined with prostacyclin and adrenomedullin in acute respiratory failure with pulmonary hypertension in piglets. Pediatr Pulmonol 42:1048-1056
44. Das S, Au E, Krazit ST, Pandey KN (2010) Targeted disruption of guanylyl cyclase-A/natriuretic peptide receptor-A gene provokes renal fibrosis and remodeling in null mutant mice: Role of proinflammatory cytokines. Endocrinology 151:5841-5850
45. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H (1981) A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 28:89-94
46. Della NG, Papka RE, Furness JB, Costa M (1983) Vasoactive intestinal peptide-like immunoreactivity in nerves associated with the cardiovascular system of guinea-pigs. Neuroscience 9:605-619
47. Desbuquois B, Laudat MH, Laudat P (1973) Vasoactive intestinal polypeptide and glucagon: Stimulation of adenylate cyclase activity via distinct receptors in liver and fat cell membranes. Biochem Biophys Res Commun 53:1187-1194
48. Dey RD, Shannon WA Jr, Said SI (1981) Localization of VIP-immunoreactive nerves in airways and pulmonary vessels of dogs, cat, and human subjects. Cell Tissue Res 220:231-238
49. Dickey DM, Flora DR, Bryan PM, Xu X, Chen Y, Potter LR (2007) Differential regulation of membrane guanylyl cyclases in congestive heart failure: NPR-B, Not NPR-A, is the predominant natriuretic peptide receptor in the failing heart. Endocrinology 148(7):3518-3522
50. Dickson L, Aramori I, Sharkey J, Finlayson K (2006) VIP and PACAP receptor pharmacology: A comparison of intracellular signaling pathways. Ann NY Acad Sci 1070:239-242
51. Dschietzig T, Richter C, Asswad L, Baumann G, Stangl K (2007) Hypoxic induction of receptor activity-modifying protein 2 alters regulation of pulmonary endothelin-1 by adrenomedullin: Induction under normoxia versus inhibition under hypoxia. J Pharmacol Exp Ther 321: 409-419
52. Dubois SK, Kishimoto I, Lillis TO, Garbers DL (2000) A genetic model defines the importance of the atrial natriuretic peptide receptor (guanylyl cyclase-A) in the regulation of kidney function. Proc Natl Acad Sci USA 97:4369-4373
53. Ellmers LJ, Scott NJA, Piuhola J, Maeda N, Smithies O, Frampton CM, Richards AM, CameronVA (2007) Npr1-regulated gene pathways contributing to cardiac hypertrophy and fibrosis. J Mol Endocrinol 38:245-257
54. Erdos EG, Skidgel RA (1989) Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J 3:145-151
55. Evgenov OV, Zou L, Zhang M, Mino-Kenudsen M, Mark EJ, Buys ES, Li Y, Feng Y, Raher MJ, Stasch JP, Chao W (2011) Stimulation of soluble guanylate cyclase attenuates bleomycininduced pulmonary fibrosis in mice. Am J Respir Crit Care Med 183:A2715
56. Fahrenkrug J, Hannibal J (2004) Neurotransmitters co-existing with VIP or PACAP. Peptides 25:393-401
57. Ferreira AJ, Shenoy V, Yamazato Y, Sriramula S, Francis J, Yuan L, Castellano RK, Ostrov DA, Oh SP, Katovich MJ, Raizada MK (2009) Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med 179:1048-1054
58. Frase LL,Gaffney FA, LaneLD, Buckey JC, Said SI, Blomqvist CG,Krejs GJ (1987) Cardiovascular effects of vasoactive intestinal peptide in healthy subjects. Am J Cardiol 60:1356-1361
59. Fraser NJ, Wise A, Brown J, McLatchie LM, Main MJ, Foord SM (1999) The amino terminus of receptor activity modifying proteins is a critical determinant of glycosylation state and ligand binding of calcitonin receptor-like receptor. Mol Pharmacol 55:1054-1059
60. Galie N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, Frost AE, Zwicke D, Naeije R, Shapiro S, Olschewski H, Rubin LJ (2005a) Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 46:529-535
61. GalieN, Boonstra A, Ewert R, Gomez-SanchezMA, Barbera JA, Torbicki A, Bremer H, Ghofrani HA, Naeije R, Gruenig E, Leuchte H, Simonneau G, Klose H, Peacock AJ, Wilkens H, Bevec D, Cavalli V, Bacher G, Rubin LJ (2010) Effects of inhaled aviptadil (vasoactive intestinal peptide) in patients with pulmonary arterial hypertension (PAH). Am J Respir Crit Care Med 181:A2516
62. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G (2005b) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353:2148-2157
63. Graf K, Koehne P, Grafe M, Zhang M, Auch-Schwelk W, Fleck E (1995) Regulation and differential expression of neutral endopeptidase 24.11 in human endothelial cells. Hypertension 26:230-235
64. Grantham JA, Schirger JA, Wennberg PW, Sandberg S, Heublein DM, Subkowski T, Burnett JC Jr (2000) Modulation of functionally active endothelin-converting enzyme by chronic neutral endopeptidase inhibition in experimental atherosclerosis. Circulation 101:1976-1981
65. Gray SL, Yamaguchi N, Vencova P, Sherwood NM (2002) Temperature-sensitive phenotype in mice lacking pituitary adenylate cyclase-activating polypeptide. Endocrinology 143:3946-3954
66. Groneberg DA, Rabe KF, Fischer A (2006) Novel concepts of neuropeptide-based drug therapy: Vasoactive intestinal polypeptide and its receptors. Eur J Pharmacol 533:182-194
67. Guan CX, Zhang M, Qin XQ, Cui YR, Luo ZQ, Bai HB, Fang X (2006) Vasoactive intestinal peptide enhances wound healing and proliferation of human bronchial epithelial cells. Peptides 27:3107-3114
68. Gunaydin S, Imai Y, Takanashi Y, Seo K, Hagino I, Chang D, Shinoka T (2002) The effects of vasoactive intestinal peptide on monocrotaline induced pulmonary hypertensive rabbits following cardiopulmonary bypass: A comparative study with isoproteronol and nitroglycerine. Cardiovasc Surg 10:138-145
69. Gutkowska J, Nemer M (1989) Structure, expression, and function of atrial natriuretic factor in extraatrial tissues. Endocr Rev 10:519-536
70. Gutkowska J, Cantin M, Genest J, Sirois P (1987) Release of immunoreactive atrial natriuretic factor from the isolated perfused rat lung. FEBS Lett 214:17-20
71. Hamidi SA, Lin RZ, Szema AM, Lyubsky S, Jiang YP, Said SI (2011) VIP and endothelin receptor antagonist: An effective combination against experimental pulmonary arterial hypertension. Respir Res 12:141
72. Harmar AJ, Marston HM, Shen S, Spratt C, West KM, Sheward WJ, Morrison CF, Dorin JR, Piggins HD, Reubi JC, Kelly JS, Maywood ES, Hastings MH (2002) The VPAC(2) receptor is essential for circadian function in the mouse suprachiasmatic nuclei. Cell 109:497-508
73. Harmar AJ, Sheward WJ, Morrison CF, Waser B, Gugger M, Reubi JC (2004) Distribution of the VPAC2 receptor in peripheral tissues of the mouse. Endocrinology 145:1203-1210
74. Hashimoto H, Ishihara T, Shigemoto R, Mori K, Nagata S (1993) Molecular cloning and tissue distribution of a receptor for pituitary adenylate cyclase-activating polypeptide. Neuron 11:333-342
75. Hashimoto H, Shintani N, Tanaka K, Mori W, Hirose M, Matsuda T, Sakaue M, Miyazaki J, Niwa H, Tashiro F, Yamamoto K, Koga K, Tomimoto S, Kunugi A, Suetake S, Baba A (2001) Altered psychomotor behaviors in mice lacking pituitary adenylate cyclase-activating polypeptide (PACAP). Proc Natl Acad Sci USA 98:13355-13360
76. Hashimoto S, Amaya F, Oh-Hashi K, Kiuchi K, Hashimoto S (2010) Expression of neutral endopeptidase activity during clinical and experimental acute lung injury. Respir Res 11:164
77. Haydar S, Sarti JF, Grisoni ER (2007) Intravenous vasoactive intestinal polypeptide lowers pulmonary-to-systemic vascular resistance ratio in a neonatal piglet model of pulmonary arterial hypertension. J Pediatr Surg 42:758-764
78. Heaton J, Lin B, Chang JK, Steinberg S, Hyman A, Lippton H (1995) Pulmonary vasodilation to adrenomedullin: A novel peptide in humans. Am J Physiol 268:H2211-H2215
79. Hegde LG, Yu C, Renner T, Thibodeaux H, Armstrong SR, Park T, Cheruvu M, Olsufka R, Sandvik ER, Lane CE, Budman J, Hill CM, Klein U, Hegde SS (2011) Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat. J Cardiovasc Pharmacol 57:495-504
80. Henning RJ, Sawmiller DR (2001) Vasoactive intestinal peptide: Cardiovascular effects. Cardiovasc Res 49:27-37
81. Hill NS, Klinger JR, Warburton RR, Pietras L, Wrenn DS (1994) Brain natriuretic peptide: Possible role in the modulation of hypoxic pulmonary hypertension. Am J Physiol 266: L308-L315
82. Hobbs AJ (1997) Soluble guanylate cyclase: The forgotten sibling. Trends Pharmacol Sci 18:484-491
83. Hobbs A, Foster P, Prescott C, Scotland R, Ahluwalia A (2004) Natriuretic peptide receptor-C regulates coronary blood flow and prevents myocardial ischemia/reperfusion injury: Novel cardioprotective role for endothelium-derived C-type natriuretic peptide. Circulation 110: 1231-1235
84. Holtwick R, van Eickels M, Skryabin BV, Baba HA, Bubikat A, Begrow F, Schneider MD, Garbers DL, Kuhn M (2003) Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest 111:1399-1407
85. Hosoya M, Kimura C, Ogi K, Ohkubo S, Miyamoto Y, Kugoh H, Shimizu M, Onda H, Oshimura M, Arimura A (1992) Structure of the human pituitary adenylate cyclase activating polypeptide (PACAP) gene. Biochim Biophys Acta 1129:199-206
86. Hosoya M, Onda H, Ogi K, Masuda Y, Miyamoto Y, Ohtaki T, Okazaki H, Arimura A, Fujino M (1993) Molecular cloning and functional expression of rat cDNAs encoding the receptor for pituitary adenylate cyclase activating polypeptide (PACAP). Biochem Biophys Res Commun 194:133-143
87. Hulks G, Jardine AG, Connell JM, Thomson NC (1990) Effect of atrial natriuretic factor on bronchomotor tone in the normal human airway. Clin Sci (Lond) 79:51-55
88. Humbert M, Sitbon O, Simonneau G (2004) Treatment of pulmonary arterial hypertension. N Engl J Med 351:1425-1436
89. Ichiki Y, Kitamura K, Kangawa K, Kawamoto M, Matsuo H, Eto T (1994) Distribution and characterization of immunoreactive adrenomedullin in human tissue and plasma. FEBS Lett 338:6-10
90. Iglarz M, Binkert C, Morrison K, Fischli W, Gatfield J, Treiber A, Weller T, Bolli MH, Boss C, Buchmann S, Capeleto B, Hess P, Qiu C, Clozel M (2008) Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 327: 736-745
91. Inagaki N, Yoshida H, Mizuta M, Mizuno N, Fujii Y, Gonoi T, Miyazaki J, Seino S (1994) Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells. Proc Natl Acad Sci USA 91:2679-2683
92. Irwin DC, Patot MT, Tucker A, Bowen R (2005) Neutral endopeptidase null mice are less susceptible to high altitude-induced pulmonary vascular leak. High Alt Med Biol 6:311-319
93. Ishigaki N, Yamamoto N, Jin H, Uchida K, Terai S, Sakaida I (2009) Continuos intravenous infusion of atrial natriuretic peptide (ANP) prevented liver fibrosis in rat. Biochem Biophys Res Commun 378:354-359
94. Ishihara T, Nakamura S, Kaziro Y, Takahashi T, Takahashi K, Nagata S (1991) Molecular cloning and expression of a cDNA encoding the secretin receptor. EMBO J 10:1635-1641
95. Ishimitsu T, Nishikimi T, Saito Y, Kitamura K, Eto T, Kangawa K,Matsuo H, Omae T,Matsuoka H (1994) Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest 94:2158-2161
96. Itoh N, Obata K, Yanaihara N, Okamoto H (1983) Human preprovasoactive intestinal polypeptide contains a novel PHI-27-like peptide, PHM-27. Nature 304:547-549
97. Ivy DD, Parker TA, Ziegler JW, Galan HL, Kinsella JP, Tuder RM, Abman SH (1997) Prolonged endothelin A receptor blockade attenuates chronic pulmonary hypertension in the ovine fetus. J Clin Invest 99:1179-1186
98. Janssen PL, Tucker A (1994) Calcitonin gene-related peptide modulates pulmonary vascular reactivity in isolated rat lungs. J Appl Physiol 77:142-146
99. Jin HK, Yang RH, Chen YF, Jackson RM, Oparil S (1988) Chronic infusion of atrial natriuretic peptide prevents pulmonary hypertension in hypoxia-adapted rats. Trans Assoc Am Physicians 101:185-192
100. Jin H, Yang RH, Chen YF, Jackson RM, Oparil S (1990) Atrial natriuretic peptide attenuates the development of pulmonary hypertension in rats adapted to chronic hypoxia. J Clin Invest 85:115-120
101. Johnson MC, McCormack RJ, Delgado M, Martinez C, Ganea D (1996) Murine T-lymphocytes express vasoactive intestinal peptide receptor 1 (VIP-R1) mRNA. J Neuroimmunol 68: 109-119
102. Kakishita M, Nishikimi T, Okano Y, Satoh T, Kyotani S, Nagaya N, Fukushima K, Nakanishi N, Takishita S, Miyata A, Kangawa K, Matsuo H, Kunieda T (1999) Increased plasma levels of adrenomedullin in patients with pulmonary hypertension. Clin Sci (Lond) 96:33-39
103. Kalk P, Godes M, Relle K, Rothkegel C, Hucke A, Stasch JP, Hocher B (2006) NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy. Br J Pharmacol 148:853-859
104. Kanazawa H, Okamoto T, Hirata K, Yoshikawa J (2000) Deletion polymorphisms in the angiotensin converting enzyme gene are associated with pulmonary hypertension evoked by exercise challenge in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 162:1235-1238
105. Kandler MA, von der Hardt K, Mahfoud S, Chada M, Schoof E, Papadopoulos T, Rascher W, Dotsch J (2003) Pilot intervention: Aerosolized adrenomedullin reduces pulmonary hypertension. J Pharmacol Exp Ther 306:1021-1026
106. Kato I, Suzuki Y, Akabane A, Yonekura H, Tanaka O, Kondo H, Takasawa S, Yoshimoto T, Okamoto H (1994) Transgenic mice overexpressing human vasoactive intestinal peptide (VIP) gene in pancreatic beta cells. Evidence for improved glucose tolerance and enhanced insulin secretion by VIP and PHM-27 in vivo. J Biol Chem 269:21223-21228
107. Keith IM (2000) The role of endogenous lung neuropeptides in regulation of the pulmonary circulation. Physiol Res 49:519-537
108. Keith IM, Ekman R (1992) Dynamic aspects of regulatory lung peptides in chronic hypoxic pulmonary hypertension. Exp Lung Res 18:205-224
109. Keith IM, Tjen AL, Kraiczi H, Ekman R (2000) Three-week neonatal hypoxia reduces blood CGRP and causes persistent pulmonary hypertension in rats. Am J Physiol Heart Circ Physiol 279:H1571-H1578
110. Kishimoto I, Dubois SK, Garbers DL (1996) The heart communicates with the kidney exclusively through the guanylyl cyclase-A receptor: Acute handling of sodium and water in response to volume expansion. Proc Natl Acad Sci USA 93:6215-6219
111. Kishimoto I, Tokudome T, Horio T, Garbers DL, Nakao K, Kangawa K (2009) Natriuretic peptide signaling via guanylyl cyclase (GC)-A: An endogenous protective mechanism of the heart. Curr Cardiol Rev 5:45-51
112. Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, Eto T (1993) Adrenomedullin: A novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 192:553-560
113. Klapholz M, Thomas I, Eng C, Iteld BJ, Ponce GA, Niederman AL, Bilsker M, Heywood JT, Synhorst D (2001) Effects of omapatrilat on hemodynamics and safety in patients with heart failure. Am J Cardiol 88:657-661
114. Klinger JR, Petit RD, Warburton RR, Wrenn DS, Arnal F, Hill NS (1993) Neutral endopeptidase inhibition attenuates development of hypoxic pulmonary hypertension in rats. J Appl Physiol 75:1615-1623
115. Klinger JR, Warburton RR, Pietras LA, Smithies O, Swift R, Hill NS (1999) Genetic disruption of atrial natriuretic peptide causes pulmonary hypertension in normoxic and hypoxic mice. Am J Physiol 276:L868-L874
116. Klinger JR, Warburton RR, Pietras L, Oliver P, Fox J, Smithies O, Hill NS (2002) Targeted disruption of the gene for natriuretic peptide receptor-A worsens hypoxia-induced cardiac hypertrophy. Am J Physiol Heart Circ Physiol 282:H58-H65
117. Klinger JR, Houtchens J, Thaker S, Hill NS, Farber H (2005) Acute cardiopulmonary hemodynamic effects of brain natriuretic peptide in patients with pulmonary arterial hypertension. Chest 128:618S-619S
118. Klinger JR, Thaker S, Houtchens J, Preston IR, Hill NS, Farber HW (2006) Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. Chest 129:417-425
119. Klinger JR, Warburton RR, Pietras L, Hill NS (1998) Brain natriuretic peptide inhibits hypoxic pulmonary hypertension in rats. J Appl Physiol 84:1646-1652
120. Knowles JW, Esposito G, Mao L, Hagaman JR, Fox JE, Smithies O, Rockman HA, MaedaN(2001) Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. J Clin Invest 107:975-984
121. Koller KJ, Goeddel DV (1992) Molecular biology of the natriuretic peptides and their receptors. Circulation 86:1081-1088
122. Koller KJ, Lowe DG, Bennett GL, Minamino N, Kangawa K, Matsuo H, Goeddel DV (1991) Selective activation of the B natriuretic peptide receptor by C-type natriuretic peptide (CNP). Science 252:120-123
123. Kralios AC, Anderson FL, Kralios FA (1990) Myocardial electrophysiological effects of vasoactive intestinal peptide in dogs. Am J Physiol 259:H1559-H1565
124. Kuhn M, Holtwick R, Baba HA, Perriard JC, Schmitz W, Ehler E (2002) Progressive cardiac hypertrophy and dysfunction in atrial natriuretic peptide receptor (GC-A) deficient mice. Heart 87:368-374
125. Langenickel TH, Buttgereit J, Pagel-Langenickel I, Lindner M, Monti J, Beuerlein K, Al Saadi N, Plehm R, Popova E, Tank J, Dietz R, Willenbrock R, Bader M (2006) Cardiac hypertrophy in transgenic rats expressing a dominant-negative mutant of the natriuretic peptide receptor B. Proc Natl Acad Sci USA 103:4735-4740
126. Larsson LI, Fahrenkrug J, de Schaffalitzky MO, Sundler F, Hakanson R, Rehfeld JR (1976) Localization of vasoactive intestinal polypeptide (VIP) to central and peripheral neurons. Proc Natl Acad Sci USA 73:3197-3200
127. Laurent S, Boutouyrie P, Azizi M, Marie C, Gros C, Schwartz JC, Lecomte JM, Bralet J (2000) Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans. Hypertension 35:1148-1153
128. Leceta J, Gomariz RP, Martinez C, Abad C, Ganea D, Delgado M (2000) Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP. Ann NY Acad Sci 921:92-102
129. Leuchte HH, Baezner C, Baumgartner RA, Bevec D, Bacher G, Neurohr C, Behr J (2008) Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J 32: 1289-1294
130. Li P, Oparil S, Novak L, Cao X, Shi W, Lucas J, Chen YF (2007) ANP signaling inhibits TGFbeta-induced Smad2 and Smad3 nuclear translocation and extracellular matrix expression in rat pulmonary arterial smooth muscle cells. J Appl Physiol 102:390-398
131. Li XW, Hu CP, Wu WH, Zhang WF, Zou XZ, Li YJ (2012) Inhibitory effect of calcitonin generelated peptide on hypoxia-induced rat pulmonary artery smooth muscle cells proliferation: Role of ERK1/2 and p27. Eur J Pharmacol 679:117-126
132. Linden A, Cardell LO, Yoshihara S, Nadel JA (1999) Bronchodilation by pituitary adenylate cyclase-activating peptide and related peptides. Eur Respir J 14:443-451
133. Linden A, Hansson L, Andersson A, Palmqvist M, Arvidsson P, Lofdahl CG, Larsson P, Lotvall J (2003) Bronchodilation by an inhaled VPAC(2) receptor agonist in patients with stable asthma. Thorax 58:217-221
134. Lippton H, Chang JK, Hao Q, Summer W, Hyman AL (1994) Adrenomedullin dilates the pulmonary vascular bed in vivo. J Appl Physiol 76:2154-2156
135. Liu LS, Cheng HY, Chin WJ, Jin HK, Oparil S (1989) Atrial natriuretic peptide lowers pulmonary arterial pressure in patients with high altitude disease. Am J Med Sci 298:397-401
136. Llorens-Cortes C, Huang H, Vicart P, Gasc JM, Paulin D, Corvol P (1992) Identification and characterization of neutral endopeptidase in endothelial cells from venous or arterial origins. J Biol Chem 267:14012-14018
137. Lopez MJ, Garbers DL, Kuhn M (1997) The guanylyl cyclase-deficient mouse defines differential pathways of natriuretic peptide signaling. J Biol Chem 272:23064-23068
138. Louzier V, Eddahibi S, Raffestin B, Deprez I, Adam M, Levame M, Eloit M, Adnot S (2001) Adenovirus-mediated atrial natriuretic protein expression in the lung protects rats from hypoxia-induced pulmonary hypertension. Hum Gene Ther 12:503-513
139. Lumsden NG, Khambata RS, Hobbs AJ (2010) C-type natriuretic peptide (CNP): Cardiovascular roles and potential as a therapeutic target. Curr Pharm Des 16:4080-4088
140. Lundberg JM, Fahrenkrug J, Hokfelt T, Martling CR, Larsson O, Tatemoto K, Anggard A (1984) Co-existence of peptide HI (PHI) and VIP in nerves regulating blood flow and bronchial smooth muscle tone in various mammals including man. Peptides 5:593-606
141. Lutz EM, Sheward WJ, West KM, Morrow JA, Fink G, Harmar AJ (1993) The VIP2 receptor: Molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett 334:3-8
142. Maack T, Suzuki M, Almeida FA, Nussenzveig D, Scarborough RM, McEnroe GA, Lewicki JA (1987) Physiological role of silent receptors of atrial natriuretic factor. Science 238:675-678
143. Mabuchi T, Shintani N, Matsumura S, Okuda-Ashitaka E, Hashimoto H, Muratani T, Minami T, Baba A, Ito S (2004) Pituitary adenylate cyclase-activating polypeptide is required for the development of spinal sensitization and induction of neuropathic pain. J Neurosci 24:7283-7291
144. Majid DS, Kadowitz PJ, Coy DH, Navar LG (1996) Renal responses to intra-arterial administration of adrenomedullin in dogs. Am J Physiol 270:F200-F205
145. Masuyama H, Tsuruda T, Sekita Y, Hatakeyama K, Imamura T, Kato J, Asada Y, Stasch JP, Kitamura K (2009) Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart. Hypertens Res 32:597-603
146. Matera MG, Calzetta L, Passeri D, Facciolo F, Rendina EA, Page C, Cazzola M, Orlandi A (2011) Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi. Br J Pharmacol 163:1740-1754
147. Matsui H, Shimosawa T, Itakura K, Guanqun X, Ando K, Fujita T (2004) Adrenomedullin can protect against pulmonary vascular remodeling induced by hypoxia. Circulation 109: 2246-2251
148. McClean DR, Ikram H, Garlick AH, Crozier IG (2001) Effects of omapatrilat on systemic arterial function in patients with chronic heart failure. Am J Cardiol 87:565-569
149. McClean DR, Ikram H,Mehta S, Heywood JT, RousseauMF, Niederman AL, Sequeira RF, Fleck E, Singh SN, Coutu B, Hanrath P, Komajda M, Bryson CC, Qian C, Hanyok JJ (2002) Vasopeptidase inhibition with omapatrilat in chronic heart failure: Acute and long-term hemodynamic and neurohumoral effects. J Am Coll Cardiol 39:2034-2041
150. McCormack DG, Mak JC, Coupe MO, Barnes PJ (1989) Calcitonin gene-related peptide vasodilation of human pulmonary vessels. J Appl Physiol 67:1265-1270
151. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, Foord SM (1998) RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393:333-339
152. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J (2009a) ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 53:1573-1619
153. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, Harrington RA, Anderson JL, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Grines CL, Hlatky MA, Jacobs AK, Kaul S, Lichtenberg RC, Lindner JR, Moliterno DJ, Mukherjee D, Pohost GM, Rosenson RS, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Weitz HH, Wesley DJ (2009b) ACCF/AHA 2009 expert consensus document on pulmonary hypertension: A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 119:2250-2294
154. Misaka S, Aoki Y, Karaki S, Kuwahara A, Mizumoto T, Onoue S, Yamada S (2010) Inhalable powder formulation of a stabilized vasoactive intestinal peptide (VIP) derivative: Antiinflammatory effect in experimental asthmatic rats. Peptides 31:72-78
155. Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L, Culler MD, Coy DH (1989) Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 164:567-574
156. Miyata A, Jiang L, Dahl RD, Kitada C, Kubo K, Fujino M, Minamino N, Arimura A (1990) Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem Biophys Res Commun 170:643-648
157. Mohapatra SS, Lockey RF, Vesely DL, Gower WR Jr (2004) Natriuretic peptides and genesis of asthma: An emerging paradigm J Allergy Clin Immunol 114:520-526
158. Morice A, Unwin RJ, Sever PS (1983) Vasoactive intestinal peptide causes bronchodilatation and protects against histamine-induced bronchoconstriction in asthmatic subjects. Lancet 2: 1225-1227
159. Morrell NW, Morris KG, Stenmark KR (1995) Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension. Am J Physiol 269: H1186-H1194
160. Morrow JA, Lutz EM, West KM, Fink G, Harmar AJ (1993) Molecular cloning and expression of a cDNA encoding a receptor for pituitary adenylate cyclase activating polypeptide (PACAP). FEBS Lett 329:99-105
161. Motte S, McEntee K, Naeije R (2006) Endothelin receptor antagonists. Pharmacol Ther 110:386-414
162. Mulderry PK, Ghatei MA, Spokes RA, Jones PM, Pierson AM, Hamid QA, Kanse S, Amara SG, Burrin JM, Legon S (1988) Differential expression of alpha-CGRP and beta-CGRP by primary sensory neurons and enteric autonomic neurons of the rat. Neuroscience 25:195-205
163. Murphy LJ, Corder R, Mallet AI, Turner AJ (1994) Generation by the phosphoramidon-sensitive peptidases, endopeptidase-24.11 and thermolysin, of endothelin-1 and c-terminal fragment from big endothelin-1. Br J Pharmacol 113:137-142
164. Murthy KS, Makhlouf GM (1994) Vasoactive intestinal peptide/pituitary adenylate cyclaseactivating peptide-dependent activation of membrane-bound NO synthase in smooth muscle mediated by pertussis toxin-sensitive Gi1-2. J Biol Chem 269:15977-15980
165. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Oya H, Kyotani S, Sakamaki F, Ueno K, Nakanishi N, Miyatake K, Kangawa K (2000a) Haemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension. Heart 84:653-658
166. Nagaya N, Satoh T, Nishikimi T, Uematsu M, Furuichi S, Sakamaki F, Oya H, Kyotani S, Nakanishi N, Goto Y, Masuda Y, Miyatake K, Kangawa K (2000b) Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation 101:498-503
167. Nagaya N, Kangawa K, Kanda M, Uematsu M, Horio T, Fukuyama N, Hino J, Harada-Shiba M, Okumura H, Tabata Y, Mochizuki N, Chiba Y, Nishioka K, Miyatake K, Asahara T, Hara H, Mori H (2003a) Hybrid cell-gene therapy for pulmonary hypertension based on phagocytosing action of endothelial progenitor cells. Circulation 108:889-895
168. Nagaya N, Miyatake K, Kyotani S, Nishikimi T, Nakanishi N, Kangawa K (2003b) Pulmonary vasodilator response to adrenomedullin in patients with pulmonary hypertension. Hypertens Res 26(Suppl):S141-S146
169. Nagaya N, Okumura H, Uematsu M, Shimizu W, Ono F, Shirai M, Mori H, Miyatake K, KangawaK (2003c) Repeated inhalation of adrenomedullin ameliorates pulmonary hypertension and survival in monocrotaline rats. Am J Physiol Heart Circ Physiol 285:H2125-H2131
170. Nagaya N, Kyotani S, Uematsu M, Ueno K, Oya H, Nakanishi N, Shirai M, Mori H, Miyatake K, Kangawa K (2004) Effects of adrenomedullin inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension. Circulation 109:351-356
171. Nakamura M, Yoshida H, Makita S, Arakawa N, Niinuma H, Hiramori K (1997) Potent and longlasting vasodilatory effects of adrenomedullin in humans. Comparisons between normal subjects and patients with chronic heart failure. Circulation 95:1214-1221
172. Nandiwada PA, Kadowitz PJ, Said SI, Mojarad M, Hyman AL (1985) Pulmonary vasodilator responses to vasoactive intestinal peptide in the cat. J Appl Physiol 58:1723-1728
173. Nanke Y, Kotake S, Akama H, Shimamoto K, Hara M, Kamatani N (2000) Raised plasma adrenomedullin patients with systemic sclerosis complicated by pulmonary hypertension. Ann Rheum Dis 59:493-494
174. Nishikimi T, Saito Y, Kitamura K, Ishimitsu T, Eto T, Kangawa K,Matsuo H, Omae T,Matsuoka H (1995) Increased plasma levels of adrenomedullin in patients with heart failure. J Am Coll Cardiol 26:1424-1431
175. Nishikimi T, Nagata S, Sasaki T, Tomimoto S, Matsuoka H, Takishita S, Kitamura K, Miyata A, Matsuo H, Kangawa K (1997) Plasma concentrations of adrenomedullin correlate with the extent of pulmonary hypertension in patients with mitral stenosis. Heart 78:390-395
176. Nishikimi T, Horio T, Yoshihara F, Nagaya N, Matsuo H, Kangawa K (1998) Effect of adrenomedullin on cAMP and cGMP levels in rat cardiac myocytes and nonmyocytes. Eur J Pharmacol 353:337-344
177. Nishikimi T, Inaba-Iemura C, Ishimura K, Tadokoro K, Koshikawa S, Ishikawa K, Akimoto K, Hattori Y, Kasai K, Minamino N, Maeda N, Matsuoka H (2009) Natriuretic peptide/natriuretic peptide receptor-A (NPR-A) system has inhibitory effects in renal fibrosis in mice. Regul Pept 154:44-53
178. Nong Z, Stassen JM, Moons L, Collen D, Janssens S (1996) Inhibition of tissue angiotensinconverting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling. Circulation 94:1941-1947
179. Nossaman BD, Feng CJ, Kaye AD, DeWitt B, Coy DH, Murphy WA, Kadowitz PJ (1996) Pulmonary vasodilator responses to adrenomedullin are reduced by NOS inhibitors in rats but not in cats. Am J Physiol 270:L782-L789
180. O'Connell JE, Jardine AG, Davidson G, Connell JM (1992) Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension. J Hypertens 10:271-277
181. O'Dorisio MS, Shannon BT, Fleshman DJ, Campolito LB (1989) Identification of high affinity receptors for vasoactive intestinal peptide on human lymphocytes of B cell lineage. J Immunol 142:3533-3536
182. Ogi K, Miyamoto Y, Masuda Y, Habata Y, Hosoya M, Ohtaki T, Masuo Y, Onda H, Fujino M (1993) Molecular cloning and functional expression of a cDNA encoding a human pituitary adenylate cyclase activating polypeptide receptor. Biochem Biophys Res Commun 196: 1511-1521
183. Ogihara T, Rakugi H, Masuo K, Yu H, Nagano M, Mikami H (1994) Antihypertensive effects of the neutral endopeptidase inhibitor SCH 42495 in essential hypertension. Am J Hypertens 7:943-947
184. Oliver PM, Fox JE, Kim R, Rockman HA, Kim HS, Reddick RL, Pandey KN, Milgram SL, Smithies O, Maeda N (1997) Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci USA 94:14730-14735
185. Onoue S, Ohmori Y, Endo K, Yamada S, Kimura R, Yajima T (2004) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide attenuate the cigarette smoke extractinduced apoptotic death of rat alveolar L2 cells. Eur J Biochem 271:1757-1767
186. Otto C, Hein L, Brede M, Jahns R, Engelhardt S, Grone HJ, Schutz G (2004) Pulmonary hypertension and right heart failure in pituitary adenylate cyclase-activating polypeptide type I receptor-deficient mice. Circulation 110:3245-3251
187. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, Swedberg K (2002) Comparison of omapatrilat and enalapril in patients with chronic heart failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 106:920-926
188. Pagel-Langenickel I, Buttgereit J, Bader M, Langenickel TH (2007) Natriuretic peptide receptor B signaling in the cardiovascular system: Protection from cardiac hypertrophy. J Mol Med (Berl) 85(8):797-810
189. Palmer JB, Cuss FM, Barnes PJ (1986) VIP and PHM and their role in nonadrenergic inhibitory responses in isolated human airways. J Appl Physiol 61:1322-1328
190. Pandey KN, Oliver PM, Maeda N, Smithies O (1999) Hypertension associated with decreased testosterone levels in natriuretic peptide receptor-A gene-knockout and gene-duplicated mutant mouse models. Endocrinology 140:5112-5119
191. Perreault T, Gutkowska J (1995) Role of atrial natriuretic factor in lung physiology and pathology. Am J Respir Crit Care Med 151:226-242
192. Petkov V, Mosgoeller W, Ziesche R, Raderer M, Stiebellehner L, Vonbank K, Funk GC, Hamilton G, Novotny C, Burian B, Block LH (2003) Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 111:1339-1346
193. Pisegna JR, Wank SA (1993) Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor. Proc Natl Acad Sci USA 90: 6345-6349
194. Popma JJ, Smitherman TC, Bedotto JB, Eichhorn EJ, Said SI, Dehmer GJ (1990) Direct coronary vasodilation induced by intracoronary vasoactive intestinal peptide. J Cardiovasc Pharmacol 16:1000-1006
195. Potter LR (2011) Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases. Pharmacol Ther 130:71-82
196. Potter LR, Abbey-Hosch S, Dickey DM (2006) Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev 27:47-72
197. Potter LR, Yoder AR, Flora DR, Antos LK, DickeyDM(2009) Natriuretic peptides: Their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol: 341-366
198. Qing X, Keith IM (2003) Targeted blocking of gene expression for CGRP receptors elevates pulmonary artery pressure in hypoxic rats. Am J Physiol Lung Cell Mol Physiol 285:L86-L96
199. Qing X, Wimalawansa SJ, Keith IM (2003) Specific N-terminal CGRP fragments mitigate chronic hypoxic pulmonary hypertension in rats. Regul Pept 110:93-99
200. Qvigstad E, Moltzau LR, Aronsen JM, Nguyen CH, Hougen K, Sjaastad I, Levy FO, Skomedal T, Osnes JB (2010) Natriuretic peptides increase beta1-adrenoceptor signalling in failing hearts through phosphodiesterase 3 inhibition. Cardiovasc Res 85:763-772
201. Rademaker MT, Charles CJ, Lewis LK, Yandle TG, Cooper GJ, Coy DH, Richards AM, Nicholls MG (1997) Beneficial hemodynamic and renal effects of adrenomedullin in an ovine model of heart failure. Circulation 96:1983-1990
202. Raffestin B, Levame M, Eddahibi S, Viossat I, Braquet P, Chabrier PE, Cantin M, Adnot S (1992) Pulmonary vasodilatory action of endogenous atrial natriuretic factor in rats with hypoxic pulmonary hypertension. Effects of monoclonal atrial natriuretic factor antibody. Circ Res 70: 184-192
203. Raizada V, Luo W, Skipper BJ, McGuire PG (2002) Intracardiac expression of neutral endopeptidase. Mol Cell Biochem 232:129-131
204. Raja SG (2010) Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis. Curr Opin Investig Drugs 11:1066-1073
205. Reubi JC (2000) In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications. Ann NY Acad Sci 921:1-25
206. Richards AM, Wittert G, Espiner EA, Yandle TG, Frampton C, Ikram H (1991) Prolonged inhibition of endopeptidase 24.11 in normal man: Renal, endocrine and haemodynamic effects. J Hypertens 9:955-962
207. Richards AM, Crozier IG, Espiner EA, Ikram H, Yandle TG, Kosoglou T, Rallings M, Frampton C (1992) Acute inhibition of endopeptidase 24.11 in essential hypertension: SCH 34826 enhances atrial natriuretic peptide and natriuresis without lowering blood pressure. J Cardiovasc Pharmacol 20:735-741
208. Richards AM, Wittert GA, Crozier IG, Espiner EA, Yandle TG, Ikram H, Frampton C (1993) Chronic inhibition of endopeptidase 24.11 in essential hypertension: Evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens 11:407-416
209. Roques BP (1998) Cell surface metallopeptidases involved in blood pressure regulation: Structure, inhibition and clinical perspectives. Pathol Biol (Paris) 46:191-200
210. Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, Porter CB, Proulx G, Qian C, Block AJ (2000) Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 356:615-620
211. Rubens C, Ewert R, Halank M, Wensel R, Orzechowski HD, Schultheiss HP, Hoeffken G (2001) Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 120:1562-1569
212. Rubinstein I (2005) Human VIP-alpha: An emerging biologic response modifier to treat primary pulmonary hypertension. Expert Rev Cardiovasc Ther 3:565-569
213. Ryan JW, Ryan US, Schultz DR, Whitaker C, Chung A (1975) Subcellular localization of pulmonary antiotensin-converting enzyme (kininase II). Biochem J 146:497-499
214. Said SI (2008) The vasoactive intestinal peptide gene is a key modulator of pulmonary vascular remodeling and inflammation. Ann NY Acad Sci 1144:148-153
215. Said SI, Mutt V (1970a) Polypeptide with broad biological activity: Isolation from small intestine. Science 169:1217-1218
216. Said SI, Mutt V (1970b) Potent peripheral and splanchnic vasodilator peptide from normal gut. Nature 225:863-864
217. Said SI, Rattan S (2004) The multiple mediators of neurogenic smooth muscle relaxation. Trends Endocrinol Metab 15:189-191
218. Said SI, Hamidi SA, Dickman KG, Szema AM, Lyubsky S, Lin RZ, Jiang YP, Chen JJ, Waschek JA, Kort S (2007) Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation 115:1260-1268
219. Sakamoto M, Nakao K, Morii N, Sugawara A, Yamada T, Itoh H, Shiono S, Saito Y, Imura H (1986) The lung as a possible target organ for atrial natriuretic polypeptide secreted from the heart. Biochem Biophys Res Commun 135:515-520
220. Sakamoto Y, Mashiko K, Saito N, Matsumoto H, Hara Y, Kutsukata N, Yokota H (2010) Effectiveness of human atrial natriuretic peptide supplementation in pulmonary edema patients using the pulse contour cardiac output system. Yonsei Med J 51:354-359
221. Sakata J, Shimokubo T, Kitamura K, Nishizono M, Iehiki Y, Kangawa K, Matsuo H, Eto T (1994) Distribution and characterization of immunoreactive rat adrenomedullin in tissue and plasma. FEBS Lett 352:105-108
222. Sato K, Oka M, Hasunuma K, Ohnishi M, Sato K, Kira S (1995) Effects of separate and combined ETA and ETB blockade on ET-1-induced constriction in perfused rat lungs. Am J Physiol 269: L668-L672
223. Schermuly RT, Weissmann N, Enke B, Ghofrani HA, Forssmann WG, Grimminger F, Seeger W, Walmrath D (2001) Urodilatin, a natriuretic peptide stimulating particulate guanylate cyclase, and the phosphodiesterase 5 inhibitor dipyridamole attenuate experimental pulmonary hypertension: Synergism upon coapplication. Am J Respir Cell Mol Biol 25:219-225
224. Schmidt DT, Ruhlmann E, Waldeck B, Branscheid D, Luts A, Sundler F, Rabe KF (2001) The effect of the vasoactive intestinal polypeptide agonist Ro 25-1553 on induced tone in isolated human airways and pulmonary artery. Naunyn Schmiedebergs Arch Pharmacol 364:314-320
225. Seymour AA, Abboa-Offei BE, Smith PL, Mathers PD, Asaad MM, Rogers WL (1995) Potentiation of natriuretic peptides by neutral endopeptidase inhibitors. Clin Exp Pharmacol Physiol 22:63-69
226. Shenoy V, Ferreira AJ, Qi Y, Fraga-Silva RA, Diez-Freire C, Dooies A, Jun JY, Sriramula S, Mariappan N, Pourang D, Venugopal CS, Francis J, Reudelhuber T, Santos RA, Patel JM, Raizada MK, Katovich MJ (2010) The angiotensin- converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 182:1065-1072
227. Shimokubo T, Sakata J, Kitamura K, Kangawa K, Matsuo H, Eto T (1995) Augmented adrenomedullin concentrations in right ventricle and plasma of experimental pulmonary hypertension. Life Sci 57:1771-1779
228. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R (2009) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54:S43-S54
229. Smitherman TC, Popma JJ, Said SI, Krejs GJ, Dehmer GJ (1989) Coronary hemodynamic effects of intravenous vasoactive intestinal peptide in humans. Am J Physiol 257:H1254-H1262
230. Solari V, Puri P (2004) Genetic polymorphisms of angiotensin system genes in congenital diaphragmatic hernia associated with persistent pulmonary hypertension. J Pediatr Surg 39: 302-306
231. Soleilhac JM, Lucas E, Beaumont A, Turcaud S, Michel JB, Ficheux D, Fournie-Zaluski MC, Roques BP (1992) A 94-kDa protein, identified as neutral endopeptidase-24.11, can inactivate atrial natriuretic peptide in the vascular endothelium. Mol Pharmacol 41:609-614
232. Solomon SD, Skali H, Bourgoun M, Fang J, Ghali JK, Martelet M, Wojciechowski D, Ansmite B, Skards J, Laks T, Henry D, Packer M, Pfeffer MA (2005) Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study. Am Heart J 150:257-262
233. Sonoyama T, Tamura N, Miyashita K, Park K, Oyamada N, Taura D, Inuzuka M, Fukunaga Y, Sone M, Nakao K (2009) Inhibition of hepatic damage and liver fibrosis by brain natriuretic peptide. FEBS Lett 583:2067-2070
234. Sreedharan SP, Patel DR, Huang JX, Goetzl EJ (1993) Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor. Biochem Biophys Res Commun 193:546-553
235. St Hilaire RC, Murthy SN, Kadowitz PJ, Jeter JR Jr (2010) Role of VPAC1 and VPAC2 in VIP mediated inhibition of rat pulmonary artery and aortic smooth muscle cell proliferation. Peptides 31:1517-1522
236. Sun JZ, Chen SJ, Li G, Chen YF (2000) Hypoxia reduces atrial natriuretic peptide clearance receptor gene expression in ANP knockout mice. Am J Physiol Lung Cell Mol Physiol 279: L511-L519
237. Sun JZ, Oparil S, Lucchesi P, Thompson JA, Chen YF (2001) Tyrosine kinase receptor activation inhibits NPR-C in lung arterial smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 281: L155-L163
238. Suzuki N, Harada M, Hosoya M, Fujino M (1994) Enhanced production of pituitary adenylatecyclase-activating polypeptide by 1, N6-dibutyryladenosine 3',5'-monophosphate, phorbol 12-myristate 13-acetate and by the polypeptide itself in human neuroblastoma cells, IMR-32. Eur J Biochem 223:147-153
239. Svoboda M, Tastenoy M, Van RJ, Goossens JF, De NP, Waelbroeck M, Robberecht P (1994) Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts. Biochem Biophys Res Commun 205:1617-1624
240. Szokodi I, Kinnunen P, Tavi P, Weckstrom M, Toth M, Ruskoaho H (1998) Evidence for cAMPindependent mechanisms mediating the effects of adrenomedullin, a new inotropic peptide. Circulation 97:1062-1070
241. Tallerico-Melnyk T, Yip CC, Watt VM (1992) Widespread co-localization of mRNAs encoding the guanylate cyclase-coupled natriuretic peptide receptors in rat tissues. Biochem Biophys Res Commun 189:610-616
242. Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, Suda M, Kasahara M, Hashimoto R, Katsuura G, Mukoyama M, Itoh H, Saito Y, Tanaka I, Otani H, Katsuki M (2000) Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA 97:4239-4244
243. Tamura N, Doolittle LK, Hammer RE, Shelton JM, Richardson JA, Garbers DL (2004) Critical roles of the guanylyl cyclase B receptor in endochondral ossification and development of female reproductive organs. Proc Natl Acad Sci USA 101:17300-17305
244. Thompson JS, Morice AH (1995) Neutral endopeptidase inhibition increases the potency of ANP in isolated rat pulmonary resistance vessels and isolated blood perfused lungs. Pulm Pharmacol 8:143-147
245. Thompson JS, Morice AH (1996) Neutral endopeptidase inhibitors and the pulmonary circulation. Gen Pharmacol 27:581-585
246. Thompson JS, Sheedy W, Morice AH (1994a) Effects of the neutral endopeptidase inhibitor, SCH 42495, on the cardiovascular remodelling secondary to chronic hypoxia in rats. Clin Sci (Lond) 87:109-114
247. Thompson JS, Sheedy W, Morice AH (1994b) Neutral endopeptidase (NEP) inhibition in rats with established pulmonary hypertension secondary to chronic hypoxia. Br J Pharmacol 113:1121-1126
248. Tjen AL, Ekman R, Lippton H, Cary J, Keith I (1992) CGRP and somatostatin modulate chronic hypoxic pulmonary hypertension. Am J Physiol 263:H681-H690
249. Tjen AL, Kraiczi H, Ekman R, Keith IM (1998) Sensory CGRP depletion by capsaicin exacerbates hypoxia-induced pulmonary hypertension in rats. Regul Pept 74:1-10
250. Tokudome T, Horio T, Soeki T, Mori K, Kishimoto I, Suga S, Yoshihara F, Kawano Y, Kohno M, Kangawa K (2004) Inhibitory effect of C-type natriuretic peptide (CNP) on cultured cardiac myocyte hypertrophy: Interference between CNP and endothelin-1 signaling pathways. Endocrinology 145:2131-2140
251. Toshimori H, Nakazato M, Toshimori K, Asai J, Matsukura S, Oura C, Matsuo H (1988) Distribution of atrial natriuretic polypeptide (ANP)-containing cells in the rat heart and pulmonary vein. Immunohistochemical study and radioimmunoassay. Cell Tissue Res 251: 541-546
252. Trippodo NC, Fox M, Monticello TM, Panchal BC, Asaad MM (1999) Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. J Cardiovasc Pharmacol 34:782-790
253. Trippodo NC, Gabel RA, Harvey CM, Asaad MM, Rogers WL (1991) Heart failure augments the cardiovascular and renal effects of neutral endopeptidase inhibition in rats. J Cardiovasc Pharmacol 18:308-316
254. Troughton RW, Rademaker MT, Powell JD, Yandle TG, Espiner EA, Frampton CM, Nicholls MG, RichardsAM(2000) Beneficial renal and hemodynamic effects of omapatrilat in mild and severe heart failure. Hypertension 36:523-530
255. Tsukada T, Horovitch SJ, Montminy MR, Mandel G, Goodman RH (1985) Structure of the human vasoactive intestinal polypeptide gene. DNA 4:293-300
256. Tucker JF, Brave SR, Charalambous L, Hobbs AJ, Gibson A (1990) L-NG-nitro arginine inhibits non-adrenergic, non-cholinergic relaxations of guinea-pig isolated tracheal smooth muscle. Br J Pharmacol 100:663-664
257. Undem BJ, Dick EC, Buckner CK (1983) Inhibition by vasoactive intestinal peptide of antigeninduced histamine release from guinea-pig minced lung. Eur J Pharmacol 88:247-250
258. Underwood DC, Bochnowicz S, Osborn RR, Louden CS, Hart TK, Ohlstein EH, Hay DW (1998) Chronic hypoxia-induced cardiopulmonary changes in three rat strains: Inhibition by the endothelin receptor antagonist SB 217242. J Cardiovasc Pharmacol 31(Suppl 1):S453-S455
259. Valentin JP, Qiu CB, Wiedemann E, Gardner D, Humphreys MH (1992) Inhibition of neutral endopeptidase amplifies the effects of endogenous atrial natriuretic peptide on blood pressure and fluid partition. Am J Hypertens 5:88-91
260. Van Geldre LA, Lefebvre RA (2004) Interaction of NO and VIP in gastrointestinal smooth muscle relaxation. Curr Pharm Des 10:2483-2497
261. Veale CA, Alford VC, Aharony D, Banville DL, Bialecki RA, Brown FJ, Damewood JR Jr, Dantzman CL, Edwards PD, Jacobs RT, Mauger RC, Murphy MM, Palmer W, Pine KK, Rumsey WL, Garcia-Davenport LE, Shaw A, Steelman GB, Surian JM, Vacek EP (2000) The discovery of non-basic atrial natriuretic peptide clearance receptor antagonists. Part 1. Bioorg Med Chem Lett 10:1949-1952
262. Velez-Roa S, Ciarka A, Najem B, Vachiery JL, Naeije R, van de Borne P (2004) Increased sympathetic nerve activity in pulmonary artery hypertension. Circulation 110:1308-1312
263. Villar IC, Panayiotou CM, Sheraz A, Madhani M, Scotland RS, Nobles M, Kemp-Harper B, Ahluwalia A, Hobbs AJ (2007) Definitive role for natriuretic peptide receptor-C in mediating the vasorelaxant activity of C-type natriuretic peptide and endothelium-derived hyperpolarising factor. Cardiovasc Res 74:515-525
264. von der Hardt K, Kandler MA, Popp K, Schoof E, Chada M, Rascher W, Dotsch J (2002) Aerosolized adrenomedullin suppresses pulmonary transforming growth factor-beta1 and interleukin-1 beta gene expression in vivo. Eur J Pharmacol 457:71-76
265. von der Hardt K, Kandler MA, Chada M, Cubra A, Schoof E, Amann K, Rascher W, Dotsch J (2004) Brief adrenomedullin inhalation leads to sustained reduction of pulmonary artery pressure. Eur Respir J 24:615-623
266. Vuckovic A, Rondelet B, Brion JP, Naeije R (2009) Expression of vasoactive intestinal peptide and related receptors in overcirculation-induced pulmonary hypertension in piglets. Pediatr Res 66:395-399
267. Wang HL, Bogen C, Reisine T, Dichter M (1989) Somatostatin-14 and somatostatin-28 induce opposite effects on potassium currents in rat neocortical neurons. Proc Natl Acad Sci USA 86:9616-9620
268. Webb DJ (1991) Endothelin receptors cloned, endothelin converting enzyme characterized and pathophysiological roles for endothelin proposed. Trends Pharmacol Sci 12:43-46
269. Williamson DJ, Wallman LL, Jones R, Keogh AM, Scroope F, Penny R, Weber C, Macdonald PS (2000) Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation 102:411-418
270. Wimalawansa SJ (1996) Calcitonin gene-related peptide and its receptors: Molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocr Rev 17:533-585
271. Winter RJ, Zhao L, Krausz T, Hughes JM (1991) Neutral endopeptidase 24.11 inhibition reduces pulmonary vascular remodeling in rats exposed to chronic hypoxia. Am Rev Respir Dis 144:1342-1346
272. Wu C, Wu F, Pan J, Morser J, Wu Q (2003) Furin-mediated processing of Pro-C-type natriuretic peptide. J Biol Chem 278:25847-25852
273. Xu J, Carretero OA, Liu YH, Yang F, Shesely EG, Oja-Tebbe N, Yang XP (2004) Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure. J Card Fail 10:83-89
274. Yamamoto K, Hashimoto H, Hagihara N, Nishino A, Fujita T, Matsuda T, Baba A (1998) Cloning and characterization of the mouse pituitary adenylate cyclase-activating polypeptide (PACAP) gene. Gene 211:63-69
275. Yamamoto T, Wada A, Tsutamoto T, Ohnishi M, Horie M (2004) Long-term treatment with a phosphodiesterase type 5 inhibitor improves pulmonary hypertension secondary to heart failure through enhancing the natriuretic peptides cGMP pathway. J Cardiovasc Pharmacol 44:596-600
276. Yamazato Y, Ferreira AJ, Hong KH, Sriramula S, Francis J, Yamazato M, Yuan L, Bradford CN, Shenoy V, Oh SP, Katovich MJ, Raizada MK (2009) Prevention of pulmonary hypertension by Angiotensin-converting enzyme 2 gene transfer. Hypertension 54:365-371
277. Yan W, Wu F, Morser J, Wu Q (2000) Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci USA 97:8525-8529
278. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411-415
279. Yang BC, Lippton H, Gumusel B, Hyman A, Mehta JL (1996) Adrenomedullin dilates rat pulmonary artery rings during hypoxia: Role of nitric oxide and vasodilator prostaglandins. J Cardiovasc Pharmacol 28:458-462
280. Yasoda A, Ogawa Y, Suda M, Tamura N, Mori K, Sakuma Y, Chusho H, Shiota K, Tanaka K, Nakao K (1998) Natriuretic peptide regulation of endochondral ossification. Evidence for possible roles of the C-type natriuretic peptide/guanylyl cyclase-B pathway. J Biol Chem 273:11695-11700
281. Yasoda A, Komatsu Y, Chusho H, Miyazawa T, Ozasa A, Miura M, Kurihara T, Rogi T, Tanaka S, Suda M, Tamura N, Ogawa Y, Nakao K (2004) Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway. Nat Med 10:80-86
282. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, Ogawa H, Okumura K, Mukoyama M, Nakao K (1994) Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90:195-203
283. Yoshibayashi M, Kamiya T, Kitamura K, Saito Y, Kangawa K, Nishikimi T, Matsuoka H, Eto T, Matsuo H (1997) Plasma levels of adrenomedullin in primary and secondary pulmonary hypertension in patients <20 years of age. Am J Cardiol 79:1556-1558
284. Yuan SH, Dai DZ, Guan L, Dai Y, Ji M (2006) CPU0507, an endothelin receptor antagonist, improves rat hypoxic pulmonary artery hypertension and constriction in vivo and in vitro. Clin Exp Pharmacol Physiol 33:1066-1072
285. Zanchi A, Maillard M, Burnier M (2003) Recent clinical trials with omapatrilat: New developments. Curr Hypertens Rep 5:346-352
286. Zhang Y, Zhang JQ, Liu ZH, Xiong CM, Ni XH, Hui RT, He JG, Pu JL (2009) VIP gene variants related to idiopathic pulmonary arterial hypertension in Chinese population. Clin Genet 75:544-549
287. Zhao L, Winter RJ, Krausz T, Hughes JM (1991) Effects of continuous infusion of atrial natriuretic peptide on the pulmonary hypertension induced by chronic hypoxia in rats. Clin Sci (Lond) 81:379-385
288. Zhao L, al-Tubuly R, Sebkhi A, Owji AA, Nunez DJ, Wilkins MR (1996a) Angiotensin II receptor expression and inhibition in the chronically hypoxic rat lung. Br J Pharmacol 119:1217-1222
289. Zhao L, Brown LA, Owji AA, Nunez DJ, Smith DM, Ghatei MA, Bloom SR, Wilkins MR (1996b) Adrenomedullin activity in chronically hypoxic rat lungs. Am J Physiol 271:H622-H629
290. Zhao L, Hughes JM, Winter RJ (1992) Effects of natriuretic peptides and neutral endopeptidase 24.11 inhibition in isolated perfused rat lung. Am Rev Respir Dis 146:1198-1201
291. Zhao L, Long L, Morrell NW, Wilkins MR (1999) NPR-A-Deficient mice show increased susceptibility to hypoxia-induced pulmonary hypertension. Circulation 99:605-607
292. Zhao L, Mason NA, Strange JW, Walker H, Wilkins MR (2003) Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity. Circulation 107:234-237
293. Zhao Q, Liu Z, Wang Z, Yang C, Liu J, Lu J (2007) Effect of prepro-calcitonin gene-related peptide-expressing endothelial progenitor cells on pulmonary hypertension. Ann Thorac Surg 84:544-552